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A One Health economic perspective allows informed decisions to be made regarding control priorities and/or
implementation strategies for infectious diseases. Schistosomiasis is a major and highly resilient disease of
both humans and livestock. The zoonotic component of transmission in sub-Saharan Africa appears to be
more significant than previously assumed, and may thereby affect the recently revised WHO vision to elimin-
ate schistosomiasis as a public health problem by 2025. Moreover, animal schistosomiasis is likely to be a sig-
nificant cost to affected communities due to its direct and indirect impact on livelihoods. We argue here for a
comprehensive evaluation of the economic burden of livestock and zoonotic schistosomiasis in sub-Saharan
Africa in order to determine if extending treatment to include animal hosts in a One Health approach is
economically, as well as epidemiologically, desirable.
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Introduction
The One Health approach recognizes that the health of humans
is connected to the health of animals and the environment, and
aims to encourage collaborative effects of multiple agencies to
achieve the best outcomes for each.1 A One Health economic
perspective that can accommodate all costs and benefits to
human and livestock sectors, as well as consideration of where
an integration of service delivery itself may have additional
cost-savings or benefits, allows informed decisions to be made
about control priorities and implementation strategies for infec-
tious diseases. For example, the proposed control of brucellosis
in Mongolia, through the vaccination of 25 million cattle, sheep
and goats at a cost of US$8 million, was initially considered eco-
nomically unjustifiable, based on the estimated US$3 million
costs of zoonotic infections to public health services alone.
However, the programme was subsequently deemed cost-
effective due to the total estimated benefit of US$26 million
when productivity losses to the human and agricultural sector
were included within a One Health economic evaluation.2
Schistosomiasis and its control in Africa
Human schistosomiasis is a chronic and debilitating neglected
tropical disease (NTD) that infects over 140 million people, with
over 90% of cases occurring in sub-Saharan Africa.3 Livestock
schistosomiasis infections due to Schistosoma bovis, Schistosoma
curassoni and/or Schistosoma matthei in cattle, sheep and goats
are also prevalent in sub-Saharan Africa, and are likely to be a
highly important, if overlooked, cause of animal mortality and
morbidity.4 S. mansoni, a causative agent of human intestinal
schistosomiasis in Africa, is acknowledged to be potentially zoo-
notic, with reservoirs in both rodents and primates.4 In contrast,
Schistosoma haematobium, the causative agent of urogenital
schistosomiasis in Africa, was originally believed to be an exclu-
sively human-specific parasite. However, morphological and sub-
sequent molecular studies of parasites isolated from, for example,
children in West Africa have identified viable hybrids of human S.
haematobium with livestock S. bovis and/or S. curassoni,5 as well
as between S. bovis with S. curassoni alone,6 demonstrating that
there is clearly a zoonotic component of transmission (see Leger
and Webster7 for a full review of zoonotic hybrid species identifi-
cation across sub-Saharan African countries).
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Current control of human schistosomiasis in Africa is based on
preventative chemotherapy (PC), whereby populations are mass
treated with the donated antihelminthic, praziquantel (PZQ). These
programmes, in general, have had impressive effects on reducing
human helminthic infection prevalence, intensity and associated
morbidity,8 to the extent that a shift towards interruption of trans-
mission has been argued for in some cases.9 Schistosome control
programmes in South and South-East Asia, where schistosomiasis
is caused by the highly zoonotic Schistosoma japonicum and/or
Schistosoma mekongi, have involved mass treatment of both
humans and bovines with PZQ, as well as essential improvements
to water, sanitation and health education, replacement of bovines
with tractors, and in some areas attempts to develop a bovine vac-
cine.10 Whilst, within certain regions of sub-Saharan Africa, some
progress in improvements to water, sanitation and health educa-
tion has been made, there are no such formal antischistosome
control or donation programmes involving animals, although there
are undocumented reports and observations of informal/unstruc-
tured treatment of animals with (locally purchased) PZQ for agricul-
tural purposes in West Africa (all authors, personal observations),
on an as-yet unquantified scale.
Concurrent treatment of zoonotic Schistosoma spp. reservoirs,
at least in terms of livestock hosts in sub-Saharan Africa (rodent
control remains a global challenge), is likely to be imperative for
successful transmission interruption of human disease.8 However,
a key problem for treatment of many zoonotic infections with
livestock reservoirs is that, while the costs of treatment fall largely
on the agricultural sector, the benefits of reduced transmission to
humans are felt largely by the public health and medical sectors.
Therefore, motivating the sustainable involvement of livestock
authorities and producers, who may have other disease priorities,
can often prove difficult.11 Economic arguments can, however,
provide a strong justification for local and national governments
to act. Given the potential impact of schistosomiasis on animal
health and productivity, a One Health economic evaluation of
extending treatment to animal hosts in sub-Saharan Africa appears
warranted, and requires data to be gathered on the costs and ben-
efits to both sectors. With a focus on economic cost aspects, we
briefly consider here the available information and highlight current
gaps in knowledge.
Cost-effectiveness of preventative chemotherapy
in humans
Preventative chemotherapy is highly cost effective, with, for
example, recent estimates of the cost effectiveness of treating
schoolchildren in Côte d’Ivoire against schistosomiasis of US$118
per disability adjusted life years (DALY) averted, as compared with
no-treatment controls.12 Further analyses have shown that
increasing coverage to include the wider community, and adults in
particular, is also highly cost effective, with an incremental cost-
effectiveness ratio of $167 per DALY averted as compared with
treating schoolchildren alone.12 Integration with other human-
focused NTD control programmes, such as those for soil-
transmitted helminthiasis, onchocerciasis and lymphatic filariasis,
has led to further cost savings within many countries across sub-
Saharan Africa.8,13 Costs vary, of course, depending on the preva-
lence of infection and are likely to increase in areas of low
prevalence, but recent work suggests that mass treatment with
PZQ is cost effective at 5% in children or 15% in whole communi-
ties, prevalences that are below current WHO treatment
guidelines.14 Estimates of cost-effectiveness in such studies are
based on the 10 clinical outcomes of schistosomiasis included in
the Global Burden of Disease studies. There is also evidence of
productivity losses in human populations due to poor school
attendance, poorer educational outcomes and reduced worker
productivity, such as through lost work days,15,16 as well as costs to
tourists of acute schistosomiasis,17 all of which have not been
assessed in current economic evaluations, suggesting that the
cost-effectiveness of human treatment may be even higher than
currently reported.
Cost-effectiveness of treatment of animal and zoonotic
schistosomiasis
The economic importance of schistosomiasis to livestock farmers
is suspected to be high, although there are substantially fewer
data available on the economic impact of schistosomiasis in ani-
mals or the cost-effectiveness of their treatment. Helminth infec-
tions of ruminants are widely acknowledged as a constraint on
efficient livestock production systems globally18 and there is
some literature available documenting the pathological effects of
schistosome infection in animals, such as of S. mattheei in cat-
tle,19 S. bovis in goats20 and S. curassoni in sheep.21 Productivity
losses may include mortality of infected animals, growth delay,
reduced meat and milk quantity and quality, and poor future
reproductive capacity.22 In Sudan, S. bovis mortality of 6–18
month old cattle was estimated at 7.1%23 and prevalences as
high as 90% were reported. There are even fewer data available
on the potential costs of treatment, including current spending
by farmers on PZQ treatment, where wide-scale treatment pro-
grammes would have additional costs, such as the strengthening
of veterinary services. Nevertheless, one economic evaluation of
human disease control in China, which did incorporate costs of
also treating bovines, reported a cost–benefit ratio of US$6.20 for
every dollar spent.24 In the only (to the authors’ knowledge) eco-
nomic evaluation of control of an animal schistosome in Africa,
through proposed vaccination of cattle in Sudan, returns ranging
from US$0.7 to 12.7 per dollar spent were estimated depending
on parasite prevalence and the costs of developing an effective
vaccine,22 although this has not yet been achieved over 30 years
later. There are, furthermore, very few data even on the preva-
lence and intensity of animal schistosomiasis in sub-Saharan
Africa, or on the relative importance of zoonotic transmission
cycles to human disease, either in the past nor under current
environments under extensive levels of anthropogenic change.4
Potential costs and caveats of a One Health Approach
The use of the same drugs in animals and humans raises pro-
found issues regarding the potential selection of PZQ resist-
ance. Veterinary use and misuse of antihelminthics increases
the risk of drug resistance evolving, particularly since common
veterinary schedules for antihelminthic treatment are often
more frequent than those used in annual human PC. Likewise,
appropriate veterinary dosages are often not as well studied
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or always implemented within developing country settings.
Furthermore, untreated zoonotic reservoirs may currently be act-
ing as a refugia, slowing the development of drug resistance.4
Co-treatment of livestock with PZQ could thus represent both an
immediate cost to human treatment programmes, if treatment
fails, and a negative externality at the societal level, due to the
reduced effectiveness of the developed drug.25 It is therefore
imperative that any extension of PZQ treatment to livestock hosts
be accompanied by the accessibility and implementation of
appropriate veterinary PZQ formulations and that all treatment
programmes must incorporate comprehensive monitoring and
evaluation within the livestock host, particularly in terms of
assessing ongoing drug efficacies, to ensure that human disease
control successes are protected.
Conclusions and recommendations
We urgently need reliable estimates of the current prevalence,
intensity and pathological burden of animal schistosomes in
affected communities in sub-Saharan Africa concurrently incorpor-
ating these data within a One Health economic evaluation of
extending disease control activities to animal hosts. Costs and
benefits are incurred in both private and public sectors for both
human health and livestock production and, therefore, we need
analyses that include human and livestock health and production
from a societal perspective. Methods now exist for the cost assign-
ment of treating zoonotic reservoirs to protect human health in
terms of DALY averted, which provide motivation to public health
authorities.2 More widespread treatment of animal schistosomes,
if seen to be medically and economically advantageous to these
communities, as well as the separate, but important potential ani-
mal welfare considerations, will require improvements in animal,
as well as human health education, strengthening of veterinary
services, accessible and affordable veterinary formulations of PZQ
(for which the authors have already observed a demand), inte-
grally combined with risk assessment and careful monitoring of
both drug supply and the potential development of drug resist-
ance throughout. Above all, this will require political will and
endorsement, across both the international and regional agendas,
as well as national and local stability. It should be remembered
that schistosomiasis, like so many coinfecting NTDs within these
communities, is a dynamic and resilient disease impacting the rur-
al poor, where in many cases it is the same families being affected
by the disease in themselves, their children and their animals,
such that costs and benefits are deeply intertwined. In the
Anthropocene epoch where multilateral organizations often set
the agenda for the poorest of the world, we have a social respon-
sibility to evaluate how this disease affects all actors and respond
accordingly and appropriately.
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